INZY INOZYME PHARMA INC revenue, earnings and financials
For the quarter ended March 31, 2025, INOZYME PHARMA INC reported revenue of n/a, net income of −$28.0M and diluted EPS of −$0.44; for the fiscal year ended December 2024 revenue was n/a.
INZY annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$104M, net income −$102M (margin n/a), EPS −$1.62
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$75.6M, net income −$71.2M (margin n/a), EPS −$1.37
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$68.7M, net income −$67.1M (margin n/a), EPS −$1.78
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$56.6M, net income −$56.6M (margin n/a), EPS −$2.40
INZY quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.0M, EPS −$0.44
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$27.1M, EPS −$0.41
- Quarter ended Sep 30, 2024: revenue n/a, net income −$24.6M, EPS −$0.39
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.0M, EPS −$0.44
- Quarter ended Mar 31, 2024: revenue n/a, net income −$23.3M, EPS −$0.38
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$21.5M, EPS −$0.33
- Quarter ended Sep 30, 2023: revenue n/a, net income −$16.6M, EPS −$0.29
- Quarter ended Jun 30, 2023: revenue n/a, net income −$15.6M, EPS −$0.35
- Quarter ended Mar 31, 2023: revenue n/a, net income −$17.4M, EPS −$0.40
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$18.5M, EPS −$0.31
- Quarter ended Sep 30, 2022: revenue n/a, net income −$16.4M, EPS −$0.38
- Quarter ended Jun 30, 2022: revenue n/a, net income −$15.3M, EPS −$0.38
- Quarter ended Mar 31, 2022: revenue n/a, net income −$16.9M, EPS −$0.71
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.8M, EPS −$0.80
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.3M, EPS −$0.60
- Quarter ended Jun 30, 2021: revenue n/a, net income −$12.5M, EPS −$0.53
- Quarter ended Mar 31, 2021: revenue n/a, net income −$11.1M, EPS −$0.47
INZY cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$91.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$70.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$57.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$48.2M, share buybacks n/a
INZY balance sheet
- Mar 31, 2025: cash $25.8M, total assets $95.2M, total liabilities $63.4M, shareholders' equity $31.8M
- Dec 31, 2024: cash $21.1M, total assets $123M, total liabilities $65.4M, shareholders' equity $57.8M
- Sep 30, 2024: cash $24.6M, total assets $143M, total liabilities $60.6M, shareholders' equity $82.8M
- Jun 30, 2024: cash $15.2M, total assets $156M, total liabilities $61.3M, shareholders' equity $94.4M
- Mar 31, 2024: cash $20.6M, total assets $177M, total liabilities $58.1M, shareholders' equity $119M
- Dec 31, 2023: cash $34.6M, total assets $201M, total liabilities $60.4M, shareholders' equity $140M
- Sep 30, 2023: cash $46.9M, total assets $206M, total liabilities $45.5M, shareholders' equity $160M
- Jun 30, 2023: cash $40.8M, total assets $151M, total liabilities $45.3M, shareholders' equity $106M
Is INZY profitable?
No. INOZYME PHARMA INC lost $107M over the last four quarters.
What is INZY's EPS?
Diluted earnings per share over the last four quarters were −$1.68; −$0.44 in the latest quarter.